Paper5779733
Control of pseudomonas infection in burns by silver sulfadiazine.
Fox CL and 2 others. Surg Gynecol Obstet, 1969. Cited by 123 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Control of pseudomonas infection in burns by silver sulfadiazine. Papers, record 5779733. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/5779733
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Burns | Major topic |
| Pseudomonas Infections | Major topic |
| Silver | Major topic |
| Sulfadiazine | Major topic |
| Adult | |
| Animals | |
| Cephalothin | |
| DNA | |
| DNA, Bacterial | |
| Female | |
| Guinea Pigs | |
| Humans | |
| Mice | |
| Military Medicine | |
| New York | |
| Ointments | |
| Protein Binding | |
| Vietnam |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31194776 | Delivery of silver sulfadiazine and adipose derived stem cells using fibrin hydrogel improves infected burn wound regeneration. | PLoS One | 2019 | https://conductscience.org/library/papers/31194776 | PubMed |
| 27642339 | Effects of Silver Sulphadiazine on Production of Extracellular Proteins by Strains of Staphylococcus Aureus Isolated from Burns Wound. | Iran J Pharm Res | 2016 | https://conductscience.org/library/papers/27642339 | PubMed |
| 23162237 | A comparative study of the effect of different topical agents on burn wound infections. | Indian J Plast Surg | 2012 | https://conductscience.org/library/papers/23162237 | PubMed |
| 19810827 | Emerging infections in burns. | Surg Infect (Larchmt) | 2009 | https://conductscience.org/library/papers/19810827 | PubMed |
| 19060724 | Concurrent in vitro release of silver sulfadiazine and bupivacaine from semi-interpenetrating networks for wound management. | J Burn Care Res | 2009 | https://conductscience.org/library/papers/19060724 | PubMed |
| 18730435 | New advances in the topical treatment of burns. | Calif Med | 1970 | https://conductscience.org/library/papers/18730435 | PubMed |
| 18165888 | Chitosan composite films. Biomedical applications. | J Mater Sci Mater Med | 2008 | https://conductscience.org/library/papers/18165888 | PubMed |
| 17377758 | [Effector molecules of the innate immune system for treatment of wound infections]. | Chirurg | 2007 | https://conductscience.org/library/papers/17377758 | PubMed |
| 16657620 | Specificity of deoxyribonucleic Acid intercalating compounds in the control of phenylalanine ammonia lyase and pisatin levels. | Plant Physiol | 1971 | https://conductscience.org/library/papers/16657620 | PubMed |
| 15973442 | Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. | Gene Ther | 2005 | https://conductscience.org/library/papers/15973442 | PubMed |
| 15825409 | Mechanism of silver sulfadiazine action on burn wound infections. | Antimicrob Agents Chemother | 1974 | https://conductscience.org/library/papers/15825409 | PubMed |
| 12019098 | Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12019098 | PubMed |
| 7574524 | Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7574524 | PubMed |
| 5000382 | Control of infection with gram-negative bacteria in patients at special risk. | Proc R Soc Med | 1971 | https://conductscience.org/library/papers/5000382 | PubMed |
| 4986877 | Mechanism of prophylaxis by silver compounds against infection of burns. | Br Med J | 1970 | https://conductscience.org/library/papers/4986877 | PubMed |
| 4791493 | Silver sulfadiazine: in vitro antibacterial activity. | Antimicrob Agents Chemother | 1973 | https://conductscience.org/library/papers/4791493 | PubMed |
| 4677596 | Silver sulfadiazine: interaction with isolated deoxyribonucleic acid. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4677596 | PubMed |
| 4597116 | Silver sulfadiazine: effect on the growth and metabolism of bacteria. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4597116 | PubMed |
| 4208294 | Silver sulfadiazine: effect on the ultrastructure of Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1973 | https://conductscience.org/library/papers/4208294 | PubMed |
| 3524422 | Mechanism of resistance to silver ions in Klebsiella pneumoniae. | Antimicrob Agents Chemother | 1986 | https://conductscience.org/library/papers/3524422 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/5779733
GET https://conductscience.org/api/papers/v1/5779733/cited_by?page=2